Ahimsa Industries Ltd Approves FY 2026 Financial Results Amid Strategic Shift to Pharmaceutical Sector
Ahimsa Industries Limited announced the approval of its audited financial results for the half year and the full financial year ended March 31, 2026. The company confirmed that its Board of Directors held a meeting on May 30, 2026, approving the results along with the auditor's report. The statutory auditors, M/s A N Shah & Associates, Chartered Accountants, issued an Audit Report with an unmodified opinion on the annual audited financial results for the year ended March 31, 2026.The company confirmed its listing status on the SME Exchange platform and noted that it does not fall under the category of 'Large Corporates'. Directors and Key Management Personnel are advised that the "Trading Window" for trading in the company's shares will open from June 02, 2026.
Financial Performance Overview
The company presented comprehensive financial statements, including the standalone balance sheet, cash flow statement, and results for the year ended March 31, 2026. The financial results highlight the following performance metrics:Statement of Standalone Results
The standalone results for the year ended March 31, 2026, show the following key figures in ₹ Lakhs:| Particulars | 6 months ended (31/03/2026) (Audited) | 6 months ended (30/09/2025) (Unaudited) | 6 months ended (31/03/2025) (Audited) | Year to date figures (31/03/2026) (Audited) | Year to date figures (31/03/2025) (Audited) |
|---|---|---|---|---|---|
| Total income from Operations (net) | 0.01 | 5.40 | 283.29 | 5.42 | 959.87 |
| Total Expenses | 27.20 | 27.78 | 540.77 | 54.98 | 1,308.76 |
| Profit/ (Loss) for the period from continuing operations | (27.19) | (22.38) | (325.76) | (49.57) | (417.63) |
| Profit/(Loss) for the period | (27.19) | (22.38) | (325.76) | (49.57) | (417.63) |
| Earnings Per Share (Basic) | 1000 | 10000 | (0.06) | (0.01) | (0.08) |
Balance Sheet Summary
The Balance Sheet, as of March 31, 2026, showed the company’s total assets and liabilities.| Particulars | As at 31/03/2026 | As at 31/03/2025 |
|---|---|---|
| Total Shareholders' funds | 809.61 | 859.16 |
| Total Non-current liabilities | 0 | 0.61 |
| Total Current liabilities | 46.55 | 23.74 |
| TOTAL - EQUITY AND LIABILITIES | 856.15 | 883.52 |
| Total Non-current assets | 127.49 | 130.39 |
| Total Current assets | 728.66 | 753.13 |
| Total -Assets | 856.15 | 883.52 |
Strategic and Accounting Updates
The company provided several key operational and accounting updates.Operational Shift and Inventory Valuation: The company announced that it discontinued its manufacturing operations. Management has been actively evaluating new business opportunities, focusing on the pharmaceutical sector as part of its strategic realignment.
In terms of inventory, management conducted a review and reassessed the Net Realisable Value (NRV) of the materials. This process led to the valuation of a portion of the inventory—which comprised aged and obsolete materials intended for food-grade applications—at NRV due to concerns regarding shelf life and product safety.
Provisioning and Contingencies:
- Provision for Doubtful Debts: The company recognized a provision for doubtful debts amounting to Rs. 2,59,46,972. This compares to Rs. 5,56,91,671 in the previous year.
- Contingent Liability: The company remains subject to pending income tax demands aggregating to approximately $9.60 Crores, which are currently under appeal before the Commissioner of Income Tax (Appeals). Management stated that, based on legal advice, no material liability is likely to arise from these proceedings.
The financial statements are prepared on a going concern basis, as management confirmed its confidence in the company's ability to continue operations under its revised structure.
Cash Flow Details
The Cash Flow Statement details the company's cash movements, highlighting the operational and investing activities.| Particulars | For the year ended 31st March 2026 | For the year ended 31st March 2025 |
|---|---|---|
| Net Profit (Loss) before taxation | (49.57) | (397.30) |
| Operating profit(loss) before working capital changes | (46.14) | (298.11) |
| Net Cash Flow from Operating Activities | (11.77) | (160.18) |
| Net Cash Flow from Investing Activities | (0.53) | 391.18 |
| Net Cash Flow from Financing Activities | (1.20) | (224.05) |
| Net Increase in Cash and Equivalent during the year | (13.50) | 6.94 |
| Cash And Cash Equivalents as at the Closing of the year | 16.52 | 30.03 |
AHIMSA Stock Price Movement
On Friday, Ahimsa Industries Limited shares settled flat, closing at ₹24.7, marking little movement for the equity. The stock traded within a tight range, finding support between ₹23.50 and ₹25.90 during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: